Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Big Pharma
Biotech
Gone are the bear days for biotech? William Blair thinks so
The analyst’s optimism is rooted in continued M&A activity, with 2025's biopharma deal volume the highest recorded in the last decade.
Gabrielle Masson
Dec 12, 2025 10:55am
Big pharma cuts and gene therapy woes: Inside Q3's layoffs
Oct 3, 2025 4:30pm
Expect further market correction in tariff-driven era: PitchBook
Apr 18, 2025 7:51am
German program matches lost NIH grants with pharma funders
Apr 7, 2025 10:50am
R&D cost per drug up year over year: Deloitte
Mar 25, 2025 12:01am
East Asians underrepresented in biopharma C-suites: report
Jan 27, 2025 3:00am
